{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:09:48Z","timestamp":1793660988762,"version":"4.5.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejmech.2026.118560","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T06:30:26Z","timestamp":1767508226000},"page":"118560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Recent development of ATR inhibitors for cancer therapy"],"prefix":"10.1016","volume":"305","author":[{"given":"Jiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wancheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118560_bib1","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019101801","article-title":"DNA damage kinase signaling: checkpoint and repair at 30 years","volume":"38","author":"Lanz","year":"2019","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.118560_bib2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118560_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118560_bib4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118560_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104536","article-title":"A function for ataxia telangiectasia and Rad3-related (ATR) kinase in cytokinetic abscission","volume":"25","author":"Luessing","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2026.118560_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118560_bib7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.gde.2021.07.003","article-title":"An extending ATR-CHK1 circuitry: the replication stress response and beyond","volume":"71","author":"Simoneau","year":"2021","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.ejmech.2026.118560_bib8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O'Connor","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.118560_bib9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118560_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41420-025-02418-8","article-title":"Perspectives on cancer therapy\u2014synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges","volume":"11","author":"Peng","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2026.118560_bib11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41416-023-02436-2","article-title":"A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours","volume":"130","author":"Burris","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118560_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/cr.2017.158","article-title":"Cryo-EM structure of human ATR-ATRIP complex","volume":"28","author":"Rao","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2026.118560_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41594-020-00522-0","article-title":"Mechanism of auto-inhibition and activation of Mec1(ATR) checkpoint kinase","volume":"28","author":"Tannous","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118560_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/10409238.2021.1925218","article-title":"Novel insights into the mechanism of cell cycle kinases Mec1(ATR) and Tel1(ATM)","volume":"56","author":"Tannous","year":"2021","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118560_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.dnarep.2018.11.002","article-title":"The Ataxia telangiectasia-mutated and Rad3-related protein kinase regulates cellular hydrogen sulfide concentrations","volume":"73","author":"Chen","year":"2019","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2026.118560_bib16","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1007\/s00018-013-1307-3","article-title":"Checkpoint kinase 1 in DNA damage response and cell cycle regulation","volume":"70","author":"Patil","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2026.118560_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118560_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179599","article-title":"ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation","volume":"9","author":"Bright","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2026.118560_bib19","doi-asserted-by":"crossref","first-page":"103662","DOI":"10.1016\/j.drudis.2023.103662","article-title":"Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic","volume":"28","author":"Priya","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118560_bib20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3892\/or.2022.8289","article-title":"ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5\u2011fluorouracil by inhibiting repair of DNA damage","volume":"47","author":"Suzuki","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2026.118560_bib21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage\u2013Inducing or Repair\u2013Compromising Therapies in Preclinical Cancer Models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118560_bib22","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.3390\/ijms25052767","article-title":"Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes","volume":"25","author":"Mavroeidi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118560_bib23","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.3390\/cancers16203536","article-title":"A TRilogy of ATR\u2019s Non-Canonical Roles Throughout the Cell Cycle and Its Relation to Cancer","volume":"16","author":"Joo","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118560_bib24","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1039\/D0MD00227E","article-title":"Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold","volume":"11","author":"Baillache","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib25","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/jhet.4593","article-title":"An insight on medicinal attributes of pyrimidine scaffold: An updated review","volume":"60","author":"Vyas","year":"2023","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib26","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity","volume":"56","author":"Foote","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib27","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent","volume":"61","author":"Foote","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1023272707390","article-title":"Lumping of whole-body physiologically based pharmacokinetic models","volume":"26","author":"Nestorov","year":"1998","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejmech.2026.118560_bib29","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/jps.10461","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans","volume":"92","author":"Luttringer","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2026.118560_bib30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijpharm.2012.02.003","article-title":"Developability assessment of clinical drug products with maximum absorbable doses","volume":"427","author":"Ding","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2026.118560_bib31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2174\/138920007780866799","article-title":"Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs","volume":"8","author":"McGinnity","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejmech.2026.118560_bib32","doi-asserted-by":"crossref","first-page":"21890","DOI":"10.1021\/acs.jmedchem.4c01595","article-title":"Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers","volume":"67","author":"Carroll","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib33","doi-asserted-by":"crossref","unstructured":"P.G. Pili\u00e9, V. Giuliani, W.L. Wang, D.J. McGrail, C.A. Bristow, N.Y.L. Ngoi, K. Kyewalabye, K.M. Wani, H. Le, E. Campbell, N.S. Sanchez, D. Yang, J.S. Gheeya, R.V. Goswamy, V. Holla, K.R. Shaw, F. Meric-Bernstam, C.Y. Liu, X. Ma, N. Feng, A.A. Machado, J.P. Bardenhagen, C.P. Vellano, J.R. Marszalek, E. Rajendra, D. Piscitello, T.I. Johnson, M. Likhatcheva, E. Elinati, J. Majithiya, J. Neves, V. Grinkevich, M. Ranzani, M.R. Luzarraga, M. Boursier, L. Armstrong, L. Geo, G. Lillo, W.Y. Tse, A.J. Lazar, S.E. Kopetz, M.K. Geck Do, S. Lively, M.G. Johnson, H.M.R. Robinson, G.C.M. Smith, C.L. Carroll, M.E. Di Francesco, P. Jones, T.P. Heffernan, T.A. Yap, Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types, Clin. Cancer Res. 30 (2024) 2121-2139.","DOI":"10.1158\/1078-0432.CCR-23-1763"},{"key":"10.1016\/j.ejmech.2026.118560_bib34","doi-asserted-by":"crossref","first-page":"114187","DOI":"10.1016\/j.ejmech.2022.114187","article-title":"Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo","volume":"232","author":"Bin","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib35","doi-asserted-by":"crossref","first-page":"153301","DOI":"10.1016\/j.phymed.2020.153301","article-title":"Polydatin alleviates high-fat diet induced atherosclerosis in apolipoprotein E-deficient mice by autophagic restoration","volume":"81","author":"Xiong","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2026.118560_bib36","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/jm800295d","article-title":"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer","volume":"51","author":"Folkes","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib37","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jmb.2017.04.006","article-title":"Rationally Designed PI3K\u03b1 Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors","volume":"429","author":"Lu","year":"2017","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118560_bib38","doi-asserted-by":"crossref","first-page":"115370","DOI":"10.1016\/j.ejmech.2023.115370","article-title":"Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase","volume":"255","author":"Duan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib39","doi-asserted-by":"crossref","first-page":"12735","DOI":"10.1021\/acs.jmedchem.4c00734","article-title":"Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib40","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1021\/acs.jmedchem.3c01917","article-title":"Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)","volume":"67","author":"Black","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib41","doi-asserted-by":"crossref","first-page":"128651","DOI":"10.1016\/j.bmcl.2022.128651","article-title":"Discovery of 6,7-dihydro-5H-pyrrolo[3,4-d] pyrimidine derivatives as a new class of ATR inhibitors","volume":"63","author":"Chen","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118560_bib42","doi-asserted-by":"crossref","first-page":"114945","DOI":"10.1016\/j.ejmech.2022.114945","article-title":"Discovery of novel 7,7-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines as ATR inhibitors based on structure-based drug design","volume":"246","author":"Qi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib43","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.3390\/molecules28114521","article-title":"Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer","volume":"28","author":"Shao","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118560_bib44","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models","volume":"63","author":"L\u00fccking","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib45","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"Charrier","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib46","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1021\/acs.jmedchem.9b00426","volume":"62","author":"Knegtel","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib47","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3390\/molecules23050992","article-title":"Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR\/mTOR Kinase Inhibitors","volume":"23","author":"Shaik","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118560_bib48","doi-asserted-by":"crossref","first-page":"116159","DOI":"10.1016\/j.ejmech.2024.116159","article-title":"Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment","volume":"267","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib49","doi-asserted-by":"crossref","first-page":"116167","DOI":"10.1016\/j.ejmech.2024.116167","article-title":"Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase","volume":"267","author":"Alfayomy","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118560_bib50","doi-asserted-by":"crossref","first-page":"15856","DOI":"10.1038\/s41598-021-95354-3","article-title":"A proteomic platform to identify off-target proteins associated with therapeutic modalities that induce protein degradation or gene silencing","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118560_bib51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.ejmech.2026.118560_bib52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s43856-024-00505-y","article-title":"Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs","volume":"4","author":"Zhang","year":"2024","journal-title":"Commun. Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T01:08:55Z","timestamp":1773536935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342600005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":52,"alternative-id":["S022352342600005X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118560","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent development of ATR inhibitors for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118560"}}